On बुधवार, Nvidia introduced a new artificial intelligence model aimed at robots and computer vision agents. The move reinforces the company's bet on the physical AI market in Japan.
Named Cosmos 3 Edge, the system is classified as a "world model," designed to help machines perceive and navigate physical environments in real time. Unlike large language models (LLMs), these systems learn from a much broader range of inputs.
The launch follows Cosmos 3, introduced in May. The regional expansion gained momentum during CEO Jensen Huang's two-day visit to the Asian country.
There, the Silicon Valley chipmaker is stitching together a coalition expected to bring together local industrial giants such as Fujitsu, Hitachi, and Kawasaki Heavy Industries, according to Nvidia itself.
"The next frontier of AI is in the physical world, and this is a unique opportunity for Japan," Huang said in a statement. "Japan invented modern manufacturing. Now, it has the opportunity to reinvent it for the era of intelligent industries."
The effort comes shortly after billion-dollar investments in Japanese territory. Microsoft allocated US$ 10 bilhões to AI infrastructure and cybersecurity, while SoftBank is seeking partnerships with Microsoft itself and Sakura Internet to develop the technology locally.
The Japanese artificial intelligence market is expected to reach US$ 27,9 bilhões by 2029, according to the International Trade Administration. Growth is supported by Tokyo's commitment to spreading AI adoption across different sectors and by the interest of local companies in forming international partnerships.
Ajay Rajadhyaksha, global head of research at Barclays, told CNBC last month that the country has an advantage in Asia thanks to strong structural growth stories.
The company is also accelerating its presence in the healthcare and biotechnology areas, with drug discovery and medical robotics initiatives. One highlight is Tokyo-1, a consortium operated by Xeureka, a Mitsui subsidiary, powered by the Nvidia BioNeMo Agent Toolkit.
Pharmaceutical companies such as Astellas, Daiichi Sankyo, and Ono Pharmaceutical already use the biology-specialized tools to optimize their workflows. In industrial automation, the partnership with Kawasaki Heavy Industries remains underway.